Risk Assessment for Myelodysplastic Syndromes

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 15, 2014
Expiration Date: May 15, 2015

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Myelodysplastic syndromes (MDS) represent one of the most common hematologic malignancies in Western countries. MDS are heterogeneous disorders ranging from indolent conditions with a near-normal life expectancy to forms approaching acute myeloid leukemia (AML). Establishing the prognosis for patients with MDS is a key element of their care because it helps patients understand the severity of their disease and set expectations for their future. For physicians, an accurate estimate of prognosis drives decisions about the timing and choice of therapeutic options to consider.

Join world-renowned expert Rami S. Komrokji, MD, associate professor of oncologic sciences of the University of South Florida College of Medicine and clinical director of the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida, as he leads a discussion of the most commonly used prognostic systems in MDS along with real-world case presentations illustrating their use both in assessing the prognosis of patients as well as their role in tailoring individualized care plans.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in the management of myelodysplastic syndromes in elderly patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Compare and contrast the most commonly used risk-stratification systems for MDS
  • Demonstrate the use of risk-stratification models in the prognosis of individual MDS patients as well as their role in tailored treatment and management planning

Agenda

Risk Assessment for Myelodysplastic Syndromes – Rami Komrokji, MD

Instructions for Participation and Credit

This activity is eligible for CME credit through May 15, 2015. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biography

Rami Komrokji, MD
Associate Professor of Oncologic Sciences
University of South Florida College of Medicine
Clinical Director
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Dr. Rami Komrokji received his medical degree from Jordan University School of Medicine and is currently pursuing a masters of public health at the University of Rochester. He completed his hematology/oncology fellowship at Strong Memorial Hospital, University of Rochester, and his internal medicine residency at Case Western Reserve. He is an associate professor of oncologic sciences at the University of South Florida College of Medicine, and clinical director in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.

Dr. Komrokji is certified by the American Board of Hematology, American Board of Medical Oncology, and American Board of Internal Medicine. He was president and on the Board of Directors of the American VA Hematology Oncology Association (AVAHO) and has held American Society of Clinical Oncology (SOHO), American Society of Hematology (ASH), and American Society of Clinical Oncology (ASCO) memberships as well. His areas of interest include myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), Hodgkin's disease, and non-Hodgkin lymphoma.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-14-010-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Rami Komrokji has received honoraria related to formal advisory activities and grant support related to research activities from Celgene Corporation and Incyte Corporation.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Komrokji has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Komrokji has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingmds.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved